Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRK5 | P34947 | 2/20 | 0.49 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.48 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.48 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.48 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.48 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.48 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 0.48 |
| ▸ | JAK3 | P52333 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | CNR1 | P21554 | 1/20 | 0.46 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6678812 | 1.00 | GRK5 (0.49) | GRK5PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL6681004 | 0.92 | GRK5 (0.47) | GRK5PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL6685061 | 0.92 | GRK5 (0.47) | GRK5PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL6835291 | 0.91 | GRK5 (0.48) | GRK5PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL6684775 | 0.91 | GRK5 (0.49) | GRK5PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL6834743 | 0.91 | GRK5 (0.48) | GRK5PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL6835415 | 0.91 | GRK5 (0.49) | GRK5PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL6835242 | 0.91 | GRK5 (0.49) | GRK5PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL6835733 | 0.91 | GRK5 (0.49) | GRK5PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL6678832 | 0.90 | GRK5 (0.47) | GRK5PSEN1PSEN2APH1BNCSTN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040043985-A1 | 6,6-Fused heteroaryl derivatives as matrix metalloproteinase inhibitors | HICKS JAMES LESTER (US) | 2004-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040043985-A1 | 6,6-Fused heteroaryl derivatives as matrix metalloproteinase inhibitors | MMP13, MMP26, MMP9 | GRK5 474/4885PSEN1 877/4885PSEN2 607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.